HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Might Pick At Nicotine Toothpick Firm's Drug, Supplement Products

Executive Summary

FDA warns Smart Toothpicks about selling nicotine-infused toothpicks to a minor and its online claim, "nicotine satisfaction without smoke damage to your lungs.” Escaping FDA attention so far are a dry mouth claim and a B12 formulation.

You may also be interested in...



GSK’s Proposal For Mouth Spray Nicorette Delayed By FDA Questions On Label

Glaxo plans to make changes FDA requested in Complete Response letter sent on 18 October, the agency’s deadline for acting on NDA for an oral spray that delivers 1 mg per spray of aqueous buffered nicotine solution for oromucosal use.

ACT Dry Mouth 'Immediate,' 'Moisturizing,' 'Lubricating' Claims OK In Review Appeal

Council of Better Business Bureaus' advertising review appeals panel says Sanofi didn't support claiming ACT Dry Mouth Lozenges "are uniquely formulated to stimulate saliva flow” because no evidence supported uniqueness. On review of initial findings from August 2018 on GSK challenge, which markets Biotene dry mouth products, panel considered appeals by both firms.

Biotene OTC Dry Mouth Competitor Remains On Market As GSK Litigates

Former Biotene owner Laclede ordered by federal judge to stop using brand, now owned by GSK, to promote its competing line of Salivea dry mouth products. But judge rejected GSK’s request that the Salivea dry mouth product marketers are subject to a lifetime non-compete agreement.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS149658

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel